← Back to Calendar

Geron Corporation Q4 2025 Earnings

Geron Corporation · $GERN

Standard Review Earnings

PDUFA Date

February 25, 2026

Time Remaining

27d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + RYTELO Rytelo commercial update

Key Notes

Q4 2025 earnings reported February 25, 2026. RYTELO Q4 revenue $48.0M (FY2025 $183.6M). 2026 revenue guidance $220M–$240M. Cash $401M. IMpactMF Phase 3 in myelofibrosis — interim OS analysis expected 2H 2026. sBLA for MDS label expansion PDUFA April 15, 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar